Available Technologies
# of Displayed Technologies: 20 / 111
Applied Category Filter (Click To Remove): Therapeutics
Breakthrough In Delivery: Expanding Access to Intracellular Targets for Next-Generation Therapies
TS-072004 — Empower your pipeline with a versatile platform for efficient, customizable biomolecule transport.
Overview
Intracellular delivery remains a persistent challenge in drug delivery, gene editing, and biotechnology. Pharmaceutical and biotech companies lose valuable opportunities when promising drugs and biologics cannot reach their intended targets inside cells, limiting product effectiveness and m…
- College: College of Arts & Sciences
- Inventors: Bong, Dennis
- Licensing Officer: Panic, Ana
Smart Blueberry Extract: The Modern Natural Health Solution for Inflammation Relief and Wellness
TS-071830 — Unlocking plant-powered solutions to deliver effective inflammation relief and enhance disease outcomes.
Overview
Chronic inflammation driven by elevated interleukin-11 (IL-11) is a critical underlying cause of tissue scarring and cancer, worsening the disease outcomes over time. Current anti-inflammatory options fall short, offering limited control over IL-11 and failing to stop its persistent buildu…
- College: College of Food, Agricultural, and Environmental Sciences (CFAES)
- Inventors: Giusti, M. Monica; Prasher, Harmeen; Sellers, Patrick; Ziouzenkova, Ouliana
- Licensing Officer: Panic, Ana
A new modular format for bispecific antibody fragments
TS-068425 — Functionalization of scFvs with cyclic peptide linkers
The Need
The high specificity of antibodies has been utilized to develop numerous technologies, tools and therapeutics, like ADCs and radiopharmaceuticals. Engineered antibody fragments like single-chain variable fragments (scFvs) are starting to see their way into the clinic in BiTEs and CAR T. Sc…
- College: College of Arts & Sciences
- Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
- Licensing Officer: Panic, Ana
Humanized SSTR2 mAb and ADC to target SSTR2+ tumors
TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment
The Liu Lab
Dr. Xiaoguang “Margaret” Liu applies her industry experience (Lonza, Merck, and Life Technologies) in cell line and process development towards her lab’s focus on targeted anti-cancer therapies including monoclonal antibodies, antibody-drug conjugates, and gene therapi…
- College: College of Engineering (COE)
- Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
- Licensing Officer: Schworer, Adam
Revolutionizing Corneal Repair: Advanced MG53-Based Treatment for Enhanced Ocular Health
TS-066878 — New and more effective treatments for corneal injuries.
Current treatments for corneal injuries often have side effects that can compromise vision, highlighting the need for a new method that enhances ocular tissue repair without such drawbacks.
The Need
Injuries to the cornea can lead to severe pain, infection, and vision loss due to scarring and abno…
- College: College of Optometry
- Inventors: Chandler, Heather; Ma, Jianjie; Tan, Tao; Zhu, Hua
- Licensing Officer: Schultz, Teri
Small Molecule USP30 Inhibitors for the Treatment and Prevention of Cardiomyopathy
TS-066773 — The Need
Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…
- College: College of Medicine (COM)
- Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
- Licensing Officer: Willson, Christopher
Cell-Penetrating Peptides: Revolutionizing Intracellular Delivery
TS-066751 —
In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Traditional methods face challenges with membrane impermeability and degradation of therapeutic compounds, limiting th…
- College: College of Arts & Sciences
- Inventors: Pei, Dehua
- Licensing Officer: Dahlman, Jason "Jay"
Innovative Small Molecule Inhibitors for Effective Treatment and Prevention of Coronavirus Infections
TS-066750 —
The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health and economies. Despite vaccine efforts, issues such as vaccine hesitancy, delays in distribution, and emerging variants have highlighted the need for effective therapeutic interventions. These i…
- College: College of Veterinary Medicine
- Inventors: Sharma, Amit; Li, Pui-Kai "Tom"; Xing, Enming
- Licensing Officer: Willson, Christopher
MG53: Enhancing Tissue Performance and Repairing Damaged Tissue
TS-066191 — , T2019-164, T2020-002, T2020-159, T2020-222: Using rhMG53 to treat conditions involving damaged tissue, including corneal repair, hepatic tissue injury, inflammatory bowel disease, and other tissue injury.
The Need
While MG53 is naturally present in skeletal and cardiac muscle, its levels are often insufficient to optimize tissue performance. Current treatments leveraging exogenous MG53 are therapeutically ineffective for conditions like multiple sclerosis, viral infections, radiation-induced tissue …
- College: College of Medicine (COM)
- Inventors: Ma, Jianjie; Tan, Tao; Zhu, Hua
- Licensing Officer: Schultz, Teri
Innovative Solutions for Cell Viability and Targeted Delivery
TS-066100 — Research tool to transfect cells ex vivo using electroporation through electrospun core-shell fibers for research applications
The Need:
Conventional electroporation methods often result in low cell viability due to heat generation, especially when working with primary cells. These methods also face challenges with non-specific transport of molecules, high vector integration rates leading to mutagenesis, and inefficacy in …
- College: College of Engineering (COE)
- Inventors: Gallego Perez, Daniel; Das, Devleena; Duarte Sanmiguel, Silvia; Higuita Castro, Natalia
- Licensing Officer: Willson, Christopher
T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need
As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Willson, Christopher
Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Willson, Christopher
Gene Therapy Approach for Treating Neuropathy
TS-065913 — Gene therapy strategies for treating peripheral neuropathy.
Peripheral neuropathy (PN) results in loss of innervation by the peripheral nerves in tissues such as skin, muscle, heart, and adipose tissue. It is a painful, debilitating disease, that is estimated to affect between 20 and 30 million Americans. The number of Americans affected by PN is likely muc…
- College: College of Medicine (COM)
- Inventors: Townsend, Kristy; Blaszkiewicz, Magdalena; Cao, Lei
- Licensing Officer: Willson, Christopher
Method for sensitizing solid tumors to immunotherapy
TS-065862 — The Need
In the landscape of cancer treatment, the emergence of immunotherapy has shown remarkable promise. However, its efficacy is not universal across all cancer types, and resistance development poses a significant challenge. Hyperprogression, characterized by accelerated tumor growth, further …
- College: College of Arts & Sciences
- Inventors: Kural, Comert; Djakbarova, Umidahan
- Licensing Officer: Wilburn, Adri
Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College of Medicine (COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Willson, Christopher
Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
- College: College of Medicine (COM)
- Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
- Licensing Officer: Willson, Christopher
Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes.
The Need
Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
- College: College of Medicine (COM)
- Inventors: Kaumaya, Pravin
- Licensing Officer: Willson, Christopher
Precision RNA-PROTACs: Revolutionizing Therapeutic Targeting of Dysregulated Ribonucleoprotein Complexes
TS-065457 — The Need:
In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…
- College: College of Arts & Sciences
- Inventors: Bong, Dennis; Liang, Yufeng; Miao, Shiqin "Shiqin"; Strong, Rebekah
- Licensing Officer: Panic, Ana
Live attenuated measles virus vaccine strains for SARS-CoV-2 vaccine
TS-065451 — The Need
The need for effective vaccine development platforms has never been more pressing, especially in the face of evolving pathogens such as the measles virus. Current vaccine production methods often face challenges in achieving optimal expression levels and immunogenicity, hindering their eff…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Li, Anzhong; Liang, Xueya; Lu, Mijia; Niewiesk, Stefan
- Licensing Officer: Willson, Christopher
Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells.
The Need
Current therapies…
- College: College of Medicine (COM)
- Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
- Licensing Officer: Willson, Christopher
